NEUROLOGICAL BIOMARKERS MARKET ANALYSIS

Neurological Biomarkers Market Size and Trends

Global neurological biomarkers market is estimated to be valued at USD 8.51 Bn in 2024 and is expected to reach USD 20.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) 13.1% from 2024 to 2031.

To learn more about this report, request sample copy

The market is expected to witness positive growth over the forecast period due to  factors such as rising incidences of neurological disorders, increasing research & development activities related to neurological diseases, rising adoption of imaging biomarkers and growing demand for minimally invasive testing. Furthermore, ongoing research to develop novel molecular biomarkers for neuropsychiatric conditions can provide opportunities for the market players. With recent technological advancements, neurological biomarkers have emerged as potential diagnostic tools and their clinical utility is under active research globally.

Rising Incidence of Neurological Disorders

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders worldwide. According to various studies, neurological disorders are becoming one of the leading causes of disability and mortality. Neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and others pose a major health burden. It is estimated that over 1 billion people suffer from some form of neurological disorder. Alzheimer's disease and epilepsy affect over 35 million and 65 million people respectively. Traumatic brain injury cases are increasing due to increasing road accidents globally. All these neurological conditions requires continuous monitoring of disease progression and treatment response through reliable biomarkers, which can aid clinical decision making. Growing incidence of neurological disorders due to growing aging population and changing lifestyle factors can boost demand for neurological biomarkers in the near future. For instance, according to the data published by WHO on March 14, 2024, a new study from the Lancet Neurology reveals that over 3 billion people globally lived with neurological conditions in 2021, making these the leading cause of illness and disability worldwide. Disability, illness, and premature death attributed to neurological conditions have increased by 18% since 1990. Most neurological deaths and health loss occur in low- and middle-income countries, where access to treatment is significantly limited compared to high-income countries.

Advances in Proteomic and Genomic Technologies

Significant technological advancements in the field of proteomics and genomics have facilitated the discovery and validation of novel neurological biomarkers. Techniques such as quantitative proteomics, mass spectrometry imaging, next generation sequencing, bioinformatics are enabling researchers to identify potential protein, genetic and metabolic biomarkers associated with different neurological conditions. For instance, technologies have helped to identify cerebrospinal fluid and blood biomarkers for Alzheimer's disease pathology as well as potential genetic variants associated with increased Parkinson's disease risk. The advancements in imaging technologies have enabled monitoring of structural and functional changes in the brain through biomarkers. Novel technologies are also aiding the development of multi-analyte biomarker panels and disease subtyping through integrated omics analysis. This is expected to revolutionize disease diagnosis, monitoring and facilitate personalized treatment approaches. Continued investments in proteomic and genomic research globally are likely to significantly contribute towards the ongoing identification and clinical adoption of novel reliable neurological biomarkers.